Apogee Therapeutics Statistics
Total Valuation
APGE has a market cap or net worth of $2.26 billion. The enterprise value is $1.63 billion.
Important Dates
The next confirmed earnings date is Monday, May 12, 2025, before market open.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
APGE has 57.20 million shares outstanding. The number of shares has increased by 57.55% in one year.
| Current Share Class | 43.72M |
| Shares Outstanding | 57.20M |
| Shares Change (YoY) | +57.55% |
| Shares Change (QoQ) | +1.65% |
| Owned by Insiders (%) | 2.20% |
| Owned by Institutions (%) | 86.69% |
| Float | 38.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.23 |
| P/TBV Ratio | 3.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.82, with a Debt / Equity ratio of 0.02.
| Current Ratio | 15.82 |
| Quick Ratio | 15.57 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -27.85% and return on invested capital (ROIC) is -20.31%.
| Return on Equity (ROE) | -27.85% |
| Return on Assets (ROA) | -19.65% |
| Return on Invested Capital (ROIC) | -20.31% |
| Return on Capital Employed (ROCE) | -35.49% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.05M |
| Employee Count | 196 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, APGE has paid $101,000 in taxes.
| Income Tax | 101,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.63% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -25.63% |
| 50-Day Moving Average | 36.42 |
| 200-Day Moving Average | 44.57 |
| Relative Strength Index (RSI) | 58.30 |
| Average Volume (20 Days) | 573,361 |
Short Selling Information
The latest short interest is 10.38 million, so 18.15% of the outstanding shares have been sold short.
| Short Interest | 10.38M |
| Short Previous Month | 9.63M |
| Short % of Shares Out | 18.15% |
| Short % of Float | 27.21% |
| Short Ratio (days to cover) | 12.05 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -241.79M |
| Pretax Income | -103.55M |
| Net Income | -205.39M |
| EBITDA | -241.42M |
| EBIT | -241.79M |
| Earnings Per Share (EPS) | -$3.59 |
Full Income StatementBalance Sheet
The company has $513.33 million in cash and $11.82 million in debt, giving a net cash position of $669.62 million or $11.71 per share.
| Cash & Cash Equivalents | 513.33M |
| Total Debt | 11.82M |
| Net Cash | 669.62M |
| Net Cash Per Share | $11.71 |
| Equity (Book Value) | 673.36M |
| Book Value Per Share | 11.55 |
| Working Capital | 488.57M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$188.02 million and capital expenditures -$5.12 million, giving a free cash flow of -$193.13 million.
| Operating Cash Flow | -188.02M |
| Capital Expenditures | -5.12M |
| Free Cash Flow | -193.13M |
| FCF Per Share | -$3.38 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |